Categories: News

Revolutionary eSight 4 Vision Assistance Device to be Showcased at Retina World Congress

Optical enhancement company attends conference with eSight 4 user to demonstrate the technology and discuss the future of vision tech

FORT LAUDERDALE, Fla., May 10, 2022 (GLOBE NEWSWIRE) — Leading vision enhancement platform, eSight, announces that it is holding demonstrations of its flagship medical device, the eSight 4, at the Retina World Congress in Fort Lauderdale, May 12 through May 15, 2022. eSight will be attending the conference with eSight 4 user Gary Foster to foster dialogue about patient needs and the future of assistive technology.

The eSight 4 is the most advanced all-in-one wearable device for people with central vision loss. Utilized by people of all ages, it houses a high-speed, high-definition camera that captures everything the wearer is looking at and presents the view on two near-to-eye OLED screens in real time with extreme clarity. Completely mobile, the eSight 4 maintains use of the wearer’s remaining peripheral vision, allowing the user to facilitate normal activities of daily living and gain independence.

In addition to offering demonstrations of the eSight 4, eSight’s leadership team will be at Retina World Congress to discuss future initiatives – particularly resulting from eSight’s recent partnership with Gentex, a leading developer of electro-optical technology. First announced in January 2022, Gentex and eSight’s partnership is aligning their technology to accelerate solutions for healthcare needs across the globe, bringing about the next generation of assistive wearable technology for those with degenerative eye diseases causing visual impairment.

“This partnership marks a monumental step for not just eSight, but the growth of assistive optical technology at large,” said eSight’s Chairman of the Board, Sam Ifergan. “eSight was founded by passionate individuals who were motivated to find solutions to macular degeneration, and this conference allows us to further that spirit of collaboration with optical professionals and researchers.”

User Gary Foster will attend this year’s conference to showcase how he uses the eSight 4 every day to help with his macular degeneration. After losing his central vision, Foster lost his job and his independence. Once he heard about eSight from his family members, he began researching his options to begin a trial for the device, and he has never looked back.

“I’ve been using eSight devices for over seven years now and it’s gotten to the point where I can’t imagine my world without them,” said Foster. “I’d love to engage with specialists and tell them my first-hand experience with eSight 4 to hopefully serve as an example for what could be possible for their patients.”

eSight and Foster will be at RWC booth #28 to demonstrate the eSight 4. To learn more about eSight and its impact, visit www.eSightEyewear.com.

About eSight
eSight is a leading vision-platform organization with a simple but profound promise: empower individuals with sight loss to see new possibilities through enhanced vision. eSight provides the most advanced and versatile assistive device available for those with visual impairments and is compatible with more than 20 eye conditions including macular degeneration, diabetic retinopathy, and Stargardt disease. eSight is registered with the FDA and EUDAMED and is inspected by Health Canada. Learn more at www.eSightEyewear.com.

Media Contact
Melanie du Mont
Uproar PR for eSight
mdumont@uproarpr.com
(321) 236-0102

Staff

Recent Posts

For Pride Month, Mental Health Professionals Offer Parenting Help

Parenting is a hard job under the best of circumstances. It can be especially confusing…

2 hours ago

Curiteva Announces the Beginning of the Commercial Launch of the Inspire(R) Posterior Interbody Solutions

HUNTSVILLE, AL / ACCESSWIRE / June 19, 2024 / Curiteva, Inc., a leading technology and…

2 hours ago

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…

2 hours ago

Sharecare announces inducement grants under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, June 19, 2024 (GLOBE NEWSWIRE) -- Sharecare (NASDAQ: SHCR), the digital health company that…

2 hours ago

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people…

2 hours ago

Calibre Scientific Acquires DCS, a German Provider of Antibodies, Reagents and Equipment Used in Immunohistochemistry

LOS ANGELES, June 19, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the…

2 hours ago